Evidence map›Paper›PMID 36555680›Full record

ArticleInternational journal of molecular sciences2022

Ivermectin Attenuates CCl

Hanglu Ying, Long Li, Yufen Zhao, Feng Ni

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hanglu YingInstitute of Drug Discovery Technology, Ningbo University, Ningbo 315211, China.
Long LiInstitute of Drug Discovery Technology, Ningbo University, Ningbo 315211, China.
Yufen ZhaoInstitute of Drug Discovery Technology, Ningbo University, Ningbo 315211, China.
Feng NiInstitute of Drug Discovery Technology, Ningbo University, Ningbo 315211, China.
Ningbo University · CN

Funding

Natural Science Foundation of Zhejiang Province LQ21H030002Ningbo Top Talent Project 215-432094250Scientific Research Grant of Ningbo University 215-432000282
6 · The paper itself

Abstract

Liver fibrosis, a common liver dysfunction with high morbidity and mortality rates, is the leading cause of cirrhosis and hepatocellular carcinoma, for which there are no effective therapies. Ivermectin is an antiparasitic drug that also has been showing therapeutic actions in many other diseases, including antiviral and anticancer actions, as well as treating metabolic diseases. Herein, we evaluated the function of ivermectin in regulating liver fibrosis. Firstly, carbon tetrachloride (CCl

Indexed as

Hepatic Stellate CellsIvermectinAnimalsCarbon TetrachlorideLiverLiver CirrhosisMiceRatsSignal TransductionTransforming Growth Factor beta1Carbon TetrachlorideIvermectinTransforming Growth Factor beta1hepatic stellate cellsinflammationivermectinliver fibrosisTGF-β1

Identifiers

PMID36555680
PMCPMC9782196
OpenAlexW4312196065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.